Nuveen Asset Management LLC Grows Stock Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Nuveen Asset Management LLC lifted its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,263,988 shares of the company's stock after buying an additional 190,830 shares during the period. Nuveen Asset Management LLC owned about 3.01% of SI-BONE worth $17,721,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. American Century Companies Inc. grew its stake in SI-BONE by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Geode Capital Management LLC grew its stake in SI-BONE by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after purchasing an additional 9,847 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of SI-BONE by 1.1% in the fourth quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock valued at $10,750,000 after buying an additional 8,240 shares during the last quarter. Pier Capital LLC lifted its position in shares of SI-BONE by 1.6% in the fourth quarter. Pier Capital LLC now owns 473,123 shares of the company's stock valued at $6,633,000 after buying an additional 7,225 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of SI-BONE by 6.3% in the fourth quarter. Northern Trust Corp now owns 409,122 shares of the company's stock valued at $5,736,000 after buying an additional 24,214 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SIBN shares. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Truist Financial raised their price objective on SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 12,385 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.67, for a total transaction of $243,612.95. Following the sale, the chief executive officer now owns 495,170 shares in the company, valued at $9,739,993.90. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 2,424 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $19.48, for a total value of $47,219.52. Following the sale, the chief financial officer now owns 222,083 shares in the company, valued at approximately $4,326,176.84. This represents a 1.08% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 92,565 shares of company stock valued at $1,669,871. Corporate insiders own 4.00% of the company's stock.

SI-BONE Stock Up 2.2%

SIBN stock traded up $0.41 during trading on Thursday, reaching $18.90. 68,644 shares of the stock were exchanged, compared to its average volume of 375,243. The firm's 50 day moving average is $15.45 and its 200 day moving average is $15.26. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The firm has a market cap of $805.38 million, a P/E ratio of -20.53 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, research analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.